Đang chuẩn bị liên kết để tải về tài liệu:
Pharmaceutical Substances Syntheses, Patents, Applications - Part 108

Pharmaceutical Substances Syntheses, Patents, Applications - Part 108. Reference containing a collection of 2267 active pharmaceutical ingredients, including those launched recently. Listed alphabetically according to their INNs and established a link between INNs, structure, synthesis and production processes, patent and literature situation, medical use, and trade names. For pharmacists and researchers | Indinavir sulfate I 1071 2.base XVI------------------------------- 1. L-tartaric acid XVII 0.7 S S-Mn H salen CI NoOCI. XIV ------------------------------------------- 4- 3-phenylpropyl pyridine N-axide XVIII oleum HjC-CN XVII XVI -------- XVIII dioxygenase bio-conversion --------------- 1S 2R -XVI1I Reference s a WO 9 309 096 Merck Co. appl. 3.11.1992 USA-prior. 8.11.1991 15.5.1992 . b WO 9 502 583 Merck Co. appl. 11.7.1994 USA-prior. 16.7.1993 . c Askin D. et al. Tetrahedron Lett. TELEAY 35 4 673 1994 . WO 9 502 584 Merck Co. appl. 11.7.1994 USA-prior. 16.7.1993 26.1.1994 . d Maligres P.E. et al. Tetrahedron Lett. TELEAY 36 2195 1995 . e WO 9 716 450 Merck Co. appl. 25.10.1996 USA-prior. 30.10.1995 22.2.1996 . f US 5 413 999 Merck Co. appl. 7.5.1993 USA-prior. 8.11.1991 . g WO 9 628 439 Merck Co. appl. 11.3.1996 USA-prior. 15.3.1995 . aa WO 9 636 629 Merck Co. appl. 14.5.1996 USA-prior. 18.5.1995 . WO 9 521 162 Merck Co. appl. 30.1.1995 USA-prior. 4.2.1994 . ab GB 2 302 690 Merck Co. appl. 20.6.1996 GB-prior. 13.2.1996 USA-prior. 28.6.1995 . ba WO 9 636 724 Merck Co. appl. 15.5.1996 USA-prior. 19.5.1995 . US 5 449 830 Merck Co. Procter Gamble Co. appl. 11.3.1994 USA-prior. 11.3.1994 . bb W0 9 700 966 Merck Co. appl. 14.6.1996 USA-prior. 13.2.1996 20.6.1995 . WO 9 612 818 Merck Co. appl. 17.10.1995 USA-prior. 21.10.1994 . reductive amination with pyridinecarboxaldehyde US 5 508 404 Merck Co. appl. 15.3.1995 USA-prior. 15.3.1995 . prodrugs of indinavir . WO 9 514 016 Merck Co. appl. 14.11.1994 USA-prior. 18.11.1993 . combination with AZT WO 9 623 509 Merck Co. appl. 29.1.1996 USA-prior. 1.2.1995 . WO 9 604 913 Merck Co. appl. 7.8.1995 USA-prior. 20.7 1995 11.8.1994 14.11.1994 . combination with e. g. neoarapine WO 9 600 068 Merck Co. appl. 23.6.1995 USA-prior. 27.6.1994 . combination with quinoxalines EP 728 481 Bayer AG appl. 14.2.1996 D-prior. 27.2.1995 . Formulation s cps. 200 mg 400 mg as sulfate 1072 I Indobufen Trade Name s D Crixivan Merck Sharp GB Crixivan